Striatal and white matter predictors of estimated diagnosis for Huntington disease.
Striatal and white matter predictors of estimated diagnosis for Huntington disease.
复制标题
DOI：
10.1016/j.brainresbull.2010.04.003
复制
发表时间：
2010-05-31
影响因子：
3.8
通讯作者：
PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG)
中科院分区：
文献类型：
--
作者：
Paulsen JS;Nopoulos PC;Aylward E;Ross CA;Johnson H;Magnotta VA;Juhl A;Pierson RK;Mills J;Langbehn D;Nance M;PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG)
先前的MRI研究中，参与者在表现出亨廷顿病之前，已经进行了小的单点样本。目前的研究报告了亨廷顿病前驱期系统性多国研究的数据，并检查了各种大脑结构是否对明显疾病的接近程度做出了独特的预测。MRI扫描来自32个PREDICT-HD研究中心之一的657名参与者。仅纳入前驱期亨廷顿病参与者（不符合运动诊断标准的参与者），并根据结合年龄和CAG重复长度的公式，按估计的诊断接近度（近、中和远）进行亚组。结果显示，所有三个亚组的总脑组织、脑脊液、白色物质、皮质灰质、丘脑、尾状核和壳核的体积与对照组显著不同。总纹状体体积显示对照组和所有三个前驱亚组之间的最大差异。大脑白色物质提供了额外的独立权力，估计接近诊断的预测。总之，这项大型横断面研究表明，在估计的亨廷顿病运动诊断之前，脑体积的变化是可检测的。这表明，一个假定的神经保护剂的临床试验可以开始多达15年前估计的运动诊断人群中的风险，但不符合临床运动诊断标准的亨廷顿病，神经影像学（纹状体和白色物质体积）可能是诊断接近的最佳预测因素。
Previous MRI studies with participants prior to manifest Huntington disease have been conducted in small single-site samples. The current study reports data from a systematic multi-national study during the prodromal period of Huntington disease and examines whether various brain structures make unique predictions about the proximity to manifest disease. MRI scans were acquired from 657 participants enrolled at one of 32 PREDICT-HD research sites. Only prodromal Huntington disease participants (those not meeting motor criteria for diagnosis) were included and subgrouped by estimated diagnosis proximity (Near, Mid, and Far) based upon a formula incorporating age and CAG repeat length. Results show volumes of all three subgroups differed significantly from Controls for total brain tissue, cerebral spinal fluid, white matter, cortical gray matter, thalamus, caudate, and putamen. Total striatal volume demonstrated the largest differences between Controls and all three prodromal subgroups. Cerebral white matter offered additional independent power in the prediction of estimated proximity to diagnosis. In conclusion, this large cross-sectional study shows that changes in brain volume are detectable years to decades prior to estimated motor diagnosis of Huntington disease. This suggests that a clinical trial of a putative neuroprotective agent could begin as much as 15 years prior to estimated motor diagnosis in a cohort of persons at risk for but not meeting clinical motor diagnostic criteria for Huntington disease, and that neuroimaging (striatal and white matter volumes) may be among the best predictors of diagnosis proximity.
登录
查看更多内容
影响因子：
--
作者：
Aylward, EH;Codori, AM;Brandt, J
通讯作者：
Brandt, J
影响因子：
11
作者：
Kipps, CM;Duggins, AJ;McCusker, EA
通讯作者：
McCusker, EA
影响因子：
17.7
作者：
Nopoulos, Peg;Magnotta, Vincent A.;Paulsen, Jane S.
通讯作者：
Paulsen, Jane S.
影响因子：
5.7
作者：
Magnotta, VA;Harris, G;Heckel, D
通讯作者：
Heckel, D
影响因子：
3.5
作者：
Langbehn, DR;Brinkman, RR;Hayden, MR
通讯作者：
Hayden, MR